Nintedanib

Chemical formula: C₃₁H₃₃N₅O₄  Molecular mass: 539.625 g/mol  PubChem compound: 9809715

Therapeutic indications

Nintedanib is indicated for:

Idiopathic pulmonary fibrosis (IPF)

Population group: only adults (18 years old or older)

Nintedanib is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell lung cancer adenocarcinoma (2nd line treatment)

Population group: only adults (18 years old or older)

Nintedanib is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.